Bristol-Myers Squibb Company (BMY) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications.

Total Revenue Chart for Bristol-Myers Squibb Company

Bristol-Myers Squibb Company (BMY) revenue for FY2025 was USD 48.2B, a -0.2% change from FY2024. Bristol-Myers Squibb Company's revenue grew from USD 7.6B in 1987 to USD 48.2B in 2025 (537.7% over 38 years). Earnings per share grew from USD 2.05 in 2000 to USD 3.46 in 2025 (68.5%). Revenue compound annual growth rate: 5-year CAGR of 2.5%, 10-year CAGR of 11.3%, 20-year CAGR of 4.7%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$127.71B
Implied Share Price
$62.48
Enterprise Value
$159.47B
Revenue (TTM)
$50.03B
EBITDA
$18.78B
Profit Margin
18.47%
Trailing P/E
13.76
Forward P/E
9.35
Price/Book (MRQ)
5.62
Price/Sales (TTM)
2.55
EV/EBITDA
9.48
EV/Revenue
3.24
Dividend Yield
1.03%
Book Value
$9.07
Free Cash Flow (FY2025)
$12.85B
Free Cash Flow Yield
10.06%

Snapshot as of 30th October 2026 — not point-in-time controlled, may lag the live market by a few days.